



MBX Biosciences to Participate in Upcoming November Investor Conferences

October 13, 2026

CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference

Date: Tuesday, November 10, 2026

Format: Fireside Chat and 1x1 meetings

Time: 11:00 – 11:25 a.m. EST

Location: Boston, MA

UBS Global Biopharma Conference

Date: Tuesday, November 17, 2026

Format: Fireside Chat and 1x1 meetings

Time: 8:00 – 8:30 a.m. GMT

Location: London, UK

Jefferies Global Healthcare Conference

Date: Wednesday, November 18, 2026

Format: Fireside Chat and 1x1 meetings

Time: 4:00 – 4:25 p.m. GMT

Location: London, UK

The live webcasts can be accessed in the events section of the MBX Biosciences website at <https://investors.mbxbio.com/news-events/events>. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company's website for approximately 90 days.

About MBX Biosciences

MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow us on [LinkedIn](#) and [X](#).

Media Contact:

George Shea

We. Communications

gshea@wecommunications.com

Investor Contact:

Pete De Spain

MBX Biosciences

pdespain@mbxbio.com